TransMedics Group, Inc. (BMV:TMDX)
Mexico · Delayed Price · Currency is MXN | Market Cap | 51.73B -30.9% |
| Revenue (ttm) | 11.68B +25.8% |
| Net Income | 2.65B +111.7% |
| EPS | 70.15 +98.9% |
| Shares Out | n/a |
| PE Ratio | 19.52 |
| Forward PE | 43.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150 |
| Open | 1,479.00 |
| Previous Close | 1,480.00 |
| Day's Range | 1,469.00 - 1,500.00 |
| 52-Week Range | 1,050.00 - 2,662.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About TransMedics Group
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung tra... [Read more]
Financial Performance
In 2025, TransMedics Group's revenue was $605.49 million, an increase of 37.13% compared to the previous year's $441.54 million. Earnings were $190.29 million, an increase of 436.58%.
Financial numbers in USD Financial StatementsNews
TransMedics Group Transcript: 2026 Global Healthcare Conference
The company highlighted robust growth, advanced technology, and a vertically integrated service model, with major expansion plans in heart, lung, and kidney transplants, and a strategic push into Europe. Long-term financial targets remain unchanged, and 2027 is expected to be a pivotal growth year.
TransMedics Group Slides: FY 2026
TransMedics Group has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 15, 2026.
TransMedics Group Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The discussion highlighted ambitious growth targets, with plans to double U.S. NOP cases by 2030, expand internationally, and launch new organ programs, especially kidney. Investments in logistics, automation, and clinical innovation are expected to drive both market share and overall transplant volume growth.
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced...
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
ANDOVER, Mass., Sept. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announce...
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
TransMedics to Present at Upcoming September Investor Conferences
ANDOVER, Mass., Aug. 31, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics Group Transcript: Canaccord Genuity's 46th Annual Growth Conference
Presented a robust, vertically integrated organ transplant platform with strong financial growth, four major expansion initiatives, and a clear path to $2–$3 billion in revenue. Strategic investments in technology, logistics, and new markets are expected to drive continued margin improvement and industry leadership.
TransMedics Group Slides: Canaccord Genuity's 46th Annual Growth Conference
TransMedics Group has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
TransMedics Group Earnings Call Transcript: Q2 2026
Record Q2 revenue of $190M was driven by strong growth in OCS case volume, clinical services, and logistics, with service revenue outpacing product revenue. Raised 2026 revenue guidance to $737–$757M, excluding PAD Aviation, and expect continued investment in growth initiatives and international expansion.
TransMedics Group Earnings release: Q2 2026
TransMedics Group released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
TransMedics Group Quarterly report: Q2 2026
TransMedics Group has published its Q2 2026 quarterly earnings report on August 4, 2026.
TransMedics Group Slides: Q2 2026
TransMedics Group has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
TransMedics Reports Second Quarter 2026 Financial Results
ANDOVER, Mass., Aug. 4, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Aug. 3, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
ANDOVER, Mass., July 28, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
ANDOVER, Mass., July 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
Strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, lays the foundation for TransMedics to establish a dedicated organ transplantation air logistics netwo...
Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating TransMedics Group, Inc. (NASDAQ: TMDX) on behalf of investors who suffered losses and whether those losses may be rec...
TransMedics Group Transcript: 46th Annual William Blair Growth Stock Conference
A transformative organ care system and vertically integrated logistics network have driven record organ utilization and double-digit growth, with ambitious targets to expand U.S. and global transplants through new technology and international partnerships. Focus remains on innovation, operational scale, and clinical excellence.
TransMedics Group Slides: 46th Annual William Blair Growth Stock Conference
TransMedics Group has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
ANDOVER, Mass., May 19, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics Group Proxy statement: Proxy filing
TransMedics Group filed a proxy statement on May 7, 2026, providing details for shareholder voting and corporate governance matters.
TransMedics Group Earnings Call Transcript: Q1 2026
Q1 2026 delivered 21% revenue growth and strong operational execution, despite regulatory headwinds and donor supply volatility. Major investments in technology, logistics, and international expansion support a reiterated 2026 revenue guidance of $727–$757 million.
TransMedics Group Earnings release: Q1 2026
TransMedics Group released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.